other material
confidence high
sentiment positive
materiality 0.60
Breakthrough T1D awards grant for SAB-142 study in Stage 3 T1D beyond 100 days
SAB Biotherapeutics, Inc.
- Breakthrough T1D awarded grant to Dr. Michael Haller (U. Florida) for PRISE-hATG study of SAB-142 in Stage 3 T1D patients 100 days to 2 years from diagnosis.
- Study aims to assess SAB-142's ability to preserve C-peptide and modulate immune responses in patients with residual beta cell function beyond 100 days.
- SAB BIO will co-fund the study; it complements ongoing Phase 2b SAFEGUARD trial in new onset Stage 3 T1D.
- CEO Samuel Reich says SAB-142 has potential as best-in-class disease-modifying therapy for T1D.